Identification and Description of Patients With High-risk Non Metastatic RCC
Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)
University Hospital, Bordeaux
6,109 participants
Apr 17, 2026
OBSERVATIONAL
Conditions
Summary
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Overall RCC Population
Non clear RCC population
Clear RCC population stratified by eligibility based on the Keynote-564 study criteria
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07753343